

Human HLA-IP + peptide elution + LC/MS/MS

Target	HLA-A allele	MS-detected peptide
KRAS(G12D)	HLA-A*11:01	VVGADGVGK, VVVGADGVGK
KRAS WT	HLA-A*11:01	VVVGAGGVGK




FIG. 1A





FIG. 1C






FIG. 2




FIG. 3A

TCR	Public NeoAg	HLA	Derived from	TRAV	TRAJ	CDR3A length	TRBV	TRBJ	CDR3B length
TCR1	RAS (G12D)	A*11:01	HD	9-2	31	14	25-1	2-1	13
TCR2	RAS (G12D)	A*11:01	Patient	38-1	57	16	5-4	1-2	15
TCR3	RAS (G12D)	A*11:01	Patient	38-2	32	15	27	1-7	16
TCR4	RAS (G12D)	A*11:01	Patient	12-3	28	17	5-1	1-1	15
TCR5	RAS (G12D)	A*11:01	Patient	5	38	14	7-8	2-3	13

FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5




FIG. 5 continued




FIG. 6A

EC ₅₀ (μM)	CD8	CD4
TCR1	2.13E-03	2.25E-01
TCR2	8.34E-03	2.09E-03
TCR3	8.38E-03	7.46E-03
TCR4	7.86E-03	1.50E-02
TCR5	8.54E-03	1.09E-02

FIG. 6B




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9A





FIG. 9B






FIG. 10C

FIG. 10D




FIG. 10E

17/19




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E